Fundraising Fox
Nektar Therapeutics
NASDAQ: NKTRSan Francisco, US · Founded 1990 · Delaware corporation · 676 employees on LinkedIn · 2 known investors
Find your way into Nektar Therapeutics
Sign up to see every warm intro you have to Nektar Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Nektar Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Nektar develops therapies that modulate the immune system to treat autoimmune diseases and inflammatory conditions, targeting the root causes of immune dysfunction. The company conducts research, therapeutic discovery, and clinical development, working with pharmaceutical partners to bring immune-mediated disease treatments to patients.
Founders & leadership
HW
Howard W. RobinExecutive
GM
Gil M. LabrucherieChief Operating Officer and Chief Financial Officer2016–2022Gil M. Labrucherie is an executive officer at Nektar Therapeutics with experience in business strategy, corporate development, and corporate finance, including capital formation and strategic partnerships in the pharmaceutical sector. He holds a CFA charter and is licensed to practice law in California.
MH
Maninder HoraChief Technical Operation Officer and SVP, Pharmaceutical Development & Manufacturing2010–2019Maninder Hora is an executive in biopharmaceutical development with over 30 years of industry experience, including more than two decades in senior leadership roles. His expertise spans drug development, manufacturing, regulatory affairs, and process optimization for biologics and small-molecule therapeutics, with direct experience engaging FDA, EMA, and other regulatory bodies on chemistry, manufacturing, and controls matters.
SK
Stephen K. DobersteinExecutive
JN
John NicholsonExecutive
JB
Jillian B. ThomsenExecutive
SG
Sandra GardinerInterim Chief Financial Officer
Board
LL
Lutz LingnauBoard director
RW
Roy WhitfieldBoard director
CA
Christopher A. KueblerBoard director
DL
Dennis L. WingerBoard director
JR
Jeff R. AjerBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$880M disclosed across 2 rounds · 2018–2024
▶$30MraisedMar 2024 · 1 investors · PharmaceuticalsRule 506(b)
▶$30MraisedMar 2024 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Roy A WhitfieldDirector
- Mark A WilsonExecutive Officer
- Sandra GardinerExecutive Officer
- Jeffrey R AjerDirector
- Howard W RobinExecutive Officer, Director
- Diana M BrainardDirector
- Robert B ChessDirector
- R. Scott GreerDirector
- Jonathan ZalevskyExecutive Officer
- Offering amount
- $30M
- Amount sold
- $30M
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$850MraisedApr 2018 · 1 investors · PharmaceuticalsRule 506(b)
▶$850MraisedApr 2018 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Lutz LingnauDirector
- Howard W. RobinExecutive Officer, Director
- Gil M. LabrucherieExecutive Officer
- Maninder HoraExecutive Officer
- Stephen K. DobersteinExecutive Officer
- John NicholsonExecutive Officer
- Roy WhitfieldDirector
- Jillian B. ThomsenExecutive Officer
- Christopher A. KueblerDirector
- Dennis L. WingerDirector
- Jeff R. AjerDirector
- R. Scott GreerDirector
- Robert ChessDirector
- Offering amount
- $850M
- Amount sold
- $850M
- First sale
- Apr 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
The Nektar Therapeutics mafia →7 people who came through Nektar Therapeutics went on to found or lead other companies.
Purnanand SarmaSeveral Roles, Sr. Dir Corporate Strategy, Dir. Research, Dir Product DevelopmentFounded Aro Biotherapeutics +2Tim HarknessSr. Vice President and CFOFounded Unchained Labs +1Anil SinghalSr. Director of OncologyFounded Trishula Therapeutics, Inc.Angela StrandVP, Marketing & Business DevelopmentFounded Precision LivestockCarlos A. SchulerSr Technical Director and Director of DesignFounded InCarda TherapeuticsJohn S. PattonCoFounder and CSOFounded InCarda TherapeuticsChristian PangratzExecutive Director - Business Development & Alliance MangementFounded Orikine Bio
Related companies · 2
MedscapeMedscape is an online platform providing medical news, clinical information, and continuing education resources to physicians and healthcare professionals globally. The platform offers CME courses, drug and disease information, and patient education across multiple specialties.
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Companies working in the same space as Nektar Therapeutics.
Frequently asked questions
- What does Nektar Therapeutics do?
- Nektar develops therapies that modulate the immune system to treat autoimmune diseases and inflammatory conditions, targeting the root causes of immune dysfunction. The company conducts research, therapeutic discovery, and clinical development, working with pharmaceutical partners to bring immune-mediated disease treatments to patients.
- Who are Nektar Therapeutics's investors?
- Nektar Therapeutics's investors include HEALTHCARE ROYALTY PARTNERS, New Enterprise Associates (NEA).
- How much funding has Nektar Therapeutics raised?
- Nektar Therapeutics has disclosed $880M raised across 2 rounds.
- Where is Nektar Therapeutics headquartered?
- Nektar Therapeutics is headquartered in San Francisco, US.